Sugemule-4 exerts anti-insomnia effects through multi-target and multi-pathway mechanisms, with apigenin, luteolin, and piplartine as core active components and EGFR as a central target.
This study identified 106 active compounds and 364 overlapping targets for Sugemule-4 in insomnia treatment. Network pharmacology and molecular docking revealed that apigenin, luteolin, and piplartine are core active components, and EGFR is a central target, potentially acting through serotonergic synapse and calcium signaling pathways.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Sugemule-4 exerts anti-insomnia effects through multi-target and multi-pathway mechanisms, with apigenin, luteolin, and piplartine as core active components and EGFR as a central target. The current body of evidence comprises 1 study. EvidenceHub rates the overall confidence at 32/100 (low).
The Claim
Sugemule-4 exerts anti-insomnia effects through multi-target and multi-pathway mechanisms, with apigenin, luteolin, and piplartine as core active components and EGFR as a central target.
This conclusion is most relevant to: Not applicable (in silico study using databases and computational models; no human or animal subjects)..
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸Prediction of the therapeutic mechanism of Sugemule-4 in insomnia treatment using network pharmacology and molecular docking. (Medicine, 2025) —
How It Works
The proposed biological pathway:
- ▸Active compounds (apigenin, luteolin, piplartine) bind to EGFR with strong affinity and form stable hydrogen bonds.
- ▸EGFR interacts with other core targets (AKT1, GAPDH, TNF, albumin) in a protein-protein interaction network.
- ▸Pathway enrichment indicates involvement of serotonergic synapse and calcium signaling pathways.
- ▸Result: Multi-target and multi-pathway anti-insomnia effects.
Who Might Benefit
Evidence fit by population:
- ▸Not applicable (in silico study using databases and computational models; no human or animal subjects).
Recommended Dose
N/A
Limitations & Caveats
Important context when interpreting this evidence:
- ▸The study is entirely computational (in silico) and lacks experimental validation in animal models or human clinical trials.
- ▸The databases used may have incomplete or biased data on active compounds and targets, potentially affecting the reliability of predictions.
Frequently Asked Questions
What are the main active compounds in Sugemule-4 for insomnia?▼
The study identified luteolin, pinocembrin, piplartine, lysicamine, and apigenin as the most active compounds, with apigenin, luteolin, and piplartine being core components.
How does Sugemule-4 work in the body to treat insomnia?▼
It acts through multiple targets and pathways, with EGFR as a central target, and involves serotonergic synapse and calcium signaling pathways.
Is there clinical evidence supporting Sugemule-4 for insomnia?▼
No, this study is based on computational predictions and has not been tested in clinical trials or animal models.
What is the role of EGFR in insomnia treatment?▼
EGFR was identified as a core target that forms stable interactions with key compounds like apigenin, luteolin, and piplartine, potentially mediating anti-insomnia effects.
References
- 1.Su R, Wang J, Su D, Su R, Sa C, Bao L. “Prediction of the therapeutic mechanism of Sugemule-4 in insomnia treatment using network pharmacology and molecular docking..” Medicine, 2025. PMID: 41367024 DOI: 10.1097/MD.0000000000046489